BC Week In Review | Jun 24, 2013
Company News

ANI Pharmaceuticals, BioSante deal

ANI and BioSante completed a stock deal under which the companies merged, with former ANI shareholders owning a 57% stake of the combined company and former BioSante shareholders owning the remaining stake. BioSante is the...
BC Week In Review | Oct 15, 2012
Company News

ANI Pharmaceuticals, BioSante deal

The companies announced they will merge in a stock deal with BioSante remaining as the surviving entity. After the deal, which is expected to close next quarter, former ANI shareholders will own about 53% of...
BC Week In Review | Sep 10, 2012
Clinical News

LibiGel testosterone: Phase III completed

BioSante stopped a double-blind, placebo-controlled, international Phase III safety trial of transdermal LibiGel because the company believes it has "adequate safety data" to support an NDA submission for LibiGel to treat HSDD in menopausal women....
BioCentury | Jul 2, 2012
Finance

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
BC Week In Review | Jun 18, 2012
Clinical News

LibiGel testosterone regulatory update

BioSante will begin 2 additional Phase III trials of LibiGel testosterone to treat hypoactive sexual desire disorder (HSDD) in menopausal women based on analysis of efficacy data, consultation with key opinion leaders and a meeting...
BC Week In Review | Feb 13, 2012
Clinical News

LibiGel testosterone: Phase III ongoing

For an eighth time, an independent DMC recommended continuation of a double-blind, placebo-controlled, international Phase III safety trial evaluating transdermal LibiGel for 12 months based on a review of safety data. The trial completed enrollment...
BioCentury | Jan 2, 2012
Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...
BC Week In Review | Dec 19, 2011
Clinical News

Testosterone: Phase III data

Top-line data from the double-blind, North American Phase III BLOOM-2 trial in 575 surgically menopausal women showed that transdermal LibiGel missed the co-primary endpoints of significantly increasing the total number of days with a satisfying...
BC Week In Review | Dec 19, 2011
Clinical News

Testosterone: Phase III data

Top-line data from the double-blind, North American Phase III BLOOM-1 trial in 597 surgically menopausal women showed that transdermal LibiGel missed the co-primary endpoints of significantly increasing the total number of days with a satisfying...
BioCentury | Dec 19, 2011
Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes Company Bank Analyst Coverage Opinion Wk chg 12/16 cls BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) Jefferies Graig Suvannavejh Downgrade Hold (from buy) -82% $0.45 Leerink Joseph Schwartz Downgrade Market perform (from market outperform)...
Items per page:
1 - 10 of 64